keyword
MENU ▼
Read by QxMD icon Read
search

secondary acute myeloid leukemia

keyword
https://www.readbyqxmd.com/read/30517910/analysis-of-efficacy-and-prognostic-factors-of-clag-treatment-in-chinese-patients-with-refractory-or-relapsed-acute-myeloid-leukemia
#1
Li Wang, Jun Xu, Xiaolong Tian, Tingting Lv, Guolin Yuan
BACKGROUND/AIMS: The aim of this work was to investigate the efficacy and predictive factors of CLAG treatment in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients. METHODS: Sixty-seven R/R AML patients were enrolled in this prospective cohort study and treated by a CLAG regimen: 5 mg/m2/day cladribine (days 1-5), 2 g/m2/day cytarabine (days 1-5), and 300 μg/day filgrastim (days 0-5). The median follow-up duration was 10 months. RESULTS: A total of 57 out of 67 patients were evaluable for remission after CLAG therapy, of whom 57...
December 5, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/30498301/neoplastic-meningitis-a-study-from-a-tertiary-care-hospital-from-coastal-india
#2
Pooja K Suresh, Jyoti Ramanath Kini, Sridevi H Basavaiah, Hema Kini, Urmila N Khadilkar, Shrijeet Chakraborti
Introduction: Neoplastic involvement of cerebrospinal fluid (CSF) secondary to known or unknown primaries elsewhere is a poor prognostic factor and is equivalent to stage IV disease. Aim: The aim of the study is to analyse the cytological features of neoplastic meningitis in a tertiary care center. Materials and Methods: A retrospective study of 400 consecutive CSF samples was done in the cytology laboratory of our hospital. The fluid obtained by spinal tap was sent for microbiological, biochemical and cytological evaluation...
October 2018: Journal of Cytology
https://www.readbyqxmd.com/read/30466744/what-biologic-factors-predict-for-transformation-to-aml
#3
REVIEW
Rafael Bejar
Transformation of myelodysplastic syndromes (MDS) into secondary acute myeloid leukemia (sAML) is defined by an arbitrary boundary of ≥20% bone marrow blasts but does not necessarily reflect a defined biological transition. The more obvious distinction lies between MDS patients that have an isolated bone marrow failure phenotype and those with excess blasts. Subtyping of MDS might be more accurately stratified into clonal cytopenias and oligoblastic leukemias, using the degree of dysplasia and blast percentage as risk features, respectively, rather than as diagnostic criteria...
December 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/30464604/nsaid-consumption-and-risk-of-acute-myeloid-leukemia-a-national-population-based-case-control-study
#4
Lene Sofie Granfeldt Østgård, Mette Nørgaard, Lars Pedersen, René Østgård, Lone Smidstrup Friis, Claudia Schöllkopf, Marianne Tang Severinsen, Claus Werenberg Marcher, Bruno C Medeiros, Morten Krogh Jensen
Background: Most cases of acute leukemia arise without identifiable risk factors. Studies investigating the impact of autoimmune diseases and infections on leukemogenesis have revealed conflicting results. If inflammation increases the risk of acute myeloid leukemia (AML), nonsteroidal anti-inflammatory drug (NSAID) use may decrease the risk of leukemia. Methods: We conducted a case-control study of 3,053 patients with AML diagnosed between 2000 and 2013, who were registered in the Danish National Acute Leukemia Registry, and 30,530 population controls matched on sex and age...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/30445237/intensive-chemotherapy-vs-hypomethylating-agents-in-older-adults-with-newly-diagnosed-high-risk-acute-myeloid-leukemia-a-single-center-experience
#5
Pankit Vachhani, Raed Al Yacoub, Austin Miller, Fan Zhang, Tara L Cronin, Evelena P Ontiveros, James E Thompson, Elizabeth A Griffiths, Eunice S Wang
Acute myeloid leukemia (AML) in older patients is often associated with biologic and clinical characteristics that predict poor outcomes to cytarabine and anthracycline based induction chemotherapy (IC). The impact of hypomethylating agents (HMA) in the treatment of these high-risk patients is unknown. Here we retrospectively examined the remission rates and survival outcomes of 201 newly diagnosed patients ≥60 years old with therapy-related (t-AML), secondary (s-AML), or AML with myelodysplasia-related changes (AML-MRC)...
December 2018: Leukemia Research
https://www.readbyqxmd.com/read/30442724/in-vitro-and-in-vivo-evaluation-of-possible-pro-survival-activities-of-pge2-egf-tpo-and-flt3l-on-human-hematopoiesis
#6
Eva-Maria Demmerath, Sheila Bohler, Mirjam Kunze, Miriam Erlacher
Myelosuppression is a major and frequently dose limiting side-effect of anticancer therapy and responsible for most treatment-related morbidity and mortality. In addition, repeated cycles of DNA damage and cell death of hematopoietic stem and progenitor cells, followed by compensatory proliferation and selection pressure, lead to genomic instability and pave the way for therapy-related myelodysplastic syndromes and secondary acute myeloid leukemia. Protection of hematopoietic stem and progenitor cells from chemo- and radiotherapy in patients with solid tumors would reduce both immediate complications and long-term sequelae...
November 15, 2018: Haematologica
https://www.readbyqxmd.com/read/30426661/identification-of-functionally-primitive-and-immunophenotypically-distinct-subpopulations-in-secondary-acute-myeloid-leukemia-by-mass-cytometry
#7
Shovik Bandyopadhyay, Jared S Fowles, Liyang Yu, Daniel A C Fisher, Stephen T Oh
BACKGROUND: Background: Mass cytometry (CyTOF) is a powerful tool for analyzing cellular networks at the single cell level. Due to the high-dimensional nature of this approach, analysis algorithms have been developed to visualize and interpret mass cytometry data. In this study, we applied these approaches to a cohort of patients with secondary acute myeloid leukemia (sAML). METHODS: We utilized mass cytometry to interrogate localization and intensity of thrombopoietin-mediated intracellular signaling in sAML...
November 13, 2018: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/30423295/jarid2-functions-as-a-tumor-suppressor-in-myeloid-neoplasms-by-repressing-self-renewal-in-hematopoietic-progenitor-cells
#8
Hamza Celik, Won Kyun Koh, Ashley C Kramer, Elizabeth L Ostrander, Cates Mallaney, Daniel A C Fisher, Jingyu Xiang, William C Wilson, Andrew Martens, Alok Kothari, Gregory Fishberger, Eric Tycksen, Darja Karpova, Eric J Duncavage, Youngsook Lee, Stephen T Oh, Grant A Challen
How specific genetic lesions contribute to transformation of non-malignant myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDSs) to secondary acute myeloid leukemia (sAML) are poorly understood. JARID2 is lost by chromosomal deletions in a proportion of MPN/MDS cases that progress to sAML. In this study, genetic mouse models and patient-derived xenografts demonstrated that JARID2 acts as a tumor suppressor in chronic myeloid disorders. Genetic deletion of Jarid2 either reduced overall survival of animals with MPNs or drove transformation to sAML, depending on the timing and context of co-operating mutations...
November 12, 2018: Cancer Cell
https://www.readbyqxmd.com/read/30407103/acute-myeloid-leukemia-in-the-elderly-what-constitutes-treatment-value
#9
Chadi Nabhan, Siddhesh Kamat, Jonathan Karl Kish
Treatment options for patients with acute myeloid leukemia (AML), who are unfit for induction chemotherapy are unsatisfactory. Overall survival (OS) superiority has not been demonstrated in randomized controlled trials (RCT) in this population, challenging the value of available therapies. We sought to assess the relative value of approved therapies using value-assessment tools. Clinical, safety, quality-of-life (QOL), supportive care, and resource utilization outcomes data were abstracted from RCTs and examined using value-assessment frameworks...
November 8, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30391189/-white-centered-retinal-hemorrhage-secondary-to-acute-myeloid-leukemia
#10
A Bennis, F Chraibi, M Abdellaoui, A I Benatiya
No abstract text is available yet for this article.
October 31, 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/30356838/leukemoid-reaction-in-infant-pertussis-is-there-a-place-for-hydroxyurea-a-case-report
#11
Guillaume Maitre, Damien Schaffner, Julia Natterer, David Longchamp, Thomas Ferry, Manuel Diezi, Stefano Di Bernardo, Marie-Hélène Perez, Vivianne Amiet
A 73-days old infant of 34 weeks' gestation was hospitalized with a co-infection of respiratory syncytial virus (RSV) and Bordetella pertussis (BP) . She required invasive ventilation for 9 days in the context of malignant pertussis with persistent hypoxemia and hypercapnia secondary to a leukemoid reaction. Despite an increase of white blood cell (WBC) count up to 70 G/L and ensuing pulmonary hypertension, no hemodynamic compromise occurred. Without clear indication for leukapheresis nor exchange transfusion, an off-label treatment with hydroxyurea was given for 5 days with gradual decrease of WBC count, without any complication and hospital discharge on day 29...
2018: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/30347595/long-non-coding-rna-taurine-upregulated-gene-1-correlates-with-unfavorable-prognosis-in-patients-with-refractory-or-relapsed-acute-myeloid-leukemia-treated-by-purine-analogue-based-chemotherapy-regimens
#12
Wenfeng Luo, Huilan Yu, Xingli Zou, Xun Ni, Jin Wei
OBJECTIVE: This study aimed to explore the correlation of long non-coding RNA taurine-upregulated gene 1 (lncRNA TUG1) expression with clinicopathological features and its predictive value for treatment response and survival profiles in refractory or relapsed acute myeloid leukemia (R/R AML) patients. METHODS: Seventy three R/R AML patients who received cladribine combined with cytarabine and granulocyte colony-stimulating factor (G-CSF) (CLAG) or fludarabine combined with cytarabine and G-CSF (FLAG) based chemotherapy and 37 non-malignant controls were recruited...
September 25, 2018: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/30332834/targeting-oncogenic-signaling-in-mutant-flt3-acute-myeloid-leukemia-the-path-to-least-resistance
#13
REVIEW
Dilana Staudt, Heather C Murray, Tabitha McLachlan, Frank Alvaro, Anoop K Enjeti, Nicole M Verrills, Matthew D Dun
The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML). The receptor tyrosine kinase FLT3 is the most commonly mutated gene in AML, with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) or missense mutations in the tyrosine kinase domain (FLT3-TKD) present in 30⁻35% of AML patients at diagnosis...
October 16, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30322915/impaired-hematopoiesis-and-leukemia-development-in-mice-with-a-conditional-knock-in-allele-of-a-mutant-splicing-factor-gene-u2af1
#14
Dennis Liang Fei, Tao Zhen, Benjamin Durham, John Ferrarone, Tuo Zhang, Lisa Garrett, Akihide Yoshimi, Omar Abdel-Wahab, Robert K Bradley, Paul Liu, Harold Varmus
Mutations affecting the spliceosomal protein U2AF1 are commonly found in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). We have generated mice that carry Cre-dependent knock-in alleles of U2af1 (S34F), the murine version of the most common mutant allele of U2AF1 encountered in human cancers. Cre-mediated recombination in murine hematopoietic lineages caused changes in RNA splicing, as well as multilineage cytopenia, macrocytic anemia, decreased hematopoietic stem and progenitor cells, low-grade dysplasias, and impaired transplantability, but without lifespan shortening or leukemia development...
October 30, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/30305508/-treatment-for-low-risk-myelodysplastic-syndromes
#15
Yasuyoshi Morita
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia and leukemic transformation. Allogeneic hematopoietic stem cell transplantation is the only potential curative therapy for MDS; however, the first treatment option for transfusion-independent patients with low-risk MDS remains limited. Recently, lenalidomide has become available for patients with low-risk MDS and symptomatic anemia with del (5q) (5q-syndrome), darbepoetin (DA) for those with anemia without del (5q), and azacitidine for those with DA-resistant anemia or anemia with thrombocytopenia...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/30295888/secondary-pulmonary-alveolar-proteinosis-in-acute-myeloid-leukemia
#16
Tetsu Hirakawa, Masaya Taniwaki, Ryouta Imanaka, Noboru Hattori
No abstract text is available yet for this article.
October 8, 2018: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/30282643/cell-lineage-level-targeted-sequencing-to-identify-acute-myeloid-leukemia-with-myelodysplasia-related-changes
#17
Kazuaki Yokoyama, Eigo Shimizu, Nozomi Yokoyama, Sousuke Nakamura, Rika Kasajima, Miho Ogawa, Tomomi Takei, Mika Ito, Asako Kobayashi, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo
Acute myeloid leukemia (AML) is a clonal myeloid neoplasm that typically arises de novo; however, some cases evolve from a preleukemic state, such as myelodysplastic syndrome (MDS). Such secondary AMLs and those with typical MDS-related clinical features are known as AMLs with myelodysplasia-related changes (AML-MRC). Because patients with AML-MRC have poor prognosis, more accurate diagnostic approaches are required. In this study, we performed targeted sequencing of 54 genes in 3 cell populations (granulocyte, blast, and T-cell fractions) using samples from 13 patients with MDS, 16 patients with clinically diagnosed AML-MRC, 4 patients with suspected AML-MRC but clinically diagnosed as AML not otherwise specified (AML-NOS), and 11 patients with de novo AML...
October 9, 2018: Blood Advances
https://www.readbyqxmd.com/read/30268525/incidence-of-secondary-myelodysplastic-syndrome-mds-and-acute-myeloid-leukemia-aml-in-patients-with-ovarian-or-breast-cancer-in-a-real-world-setting-in-the-united-states
#18
Rahul Shenolikar, Emily Durden, Nicole Meyer, Gregory Lenhart, Kathleen Moore
OBJECTIVE: Real-world data on patients with cancer developing secondary malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are lacking. This study assessed the incidence and impact of select DNA-damaging therapy exposure on risk of secondary MDS and AML in patients with ovarian cancer (OC) or breast cancer (BC). METHODS: Adults with a first observed OC or BC diagnosis (index date) between 1/1/2000 and 6/30/2014 were identified from MarketScan® Commercial and Medicare databases...
November 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/30260758/improved-survival-by-adding-lomustine-to-conventional-chemotherapy-for-elderly-patients-with-aml-without-unfavorable-cytogenetics-results-of-the-lam-sa-2007-filo-trial
#19
Arnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, Pierre-Yves Dumas, Jacques Delaunay, Caroline Bonmati, Romain Guièze, Isabelle Luquet, Pascale Cornillet-Lefebvre, Eric Delabesse, Jean-Christophe Ianotto, Mario Ojeda-Uribe, Mathilde Hunault, Anne Banos, Luc Matthieu Fornecker, Marc Bernard, Eric Jourdan, Norbert Vey, Hacene Zerazhi, Yosr Hishri, Ariane Mineur, Julien Asselineau, Roselyne Delepine, Jean-Yves Cahn, Norbert Ifrah, Christian Récher
PURPOSE: Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, the prospective open-label phase III LAM-SA 2007 (Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old) trial randomly assigned patients to a standard induction regimen with lomustine added or to a consolidation regimen with cytarabine and idarubicin...
September 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30253387/the-risk-of-clonal-evolution-of-granulocyte-colony-stimulating-factor-for-acquired-aplastic-anemia-a-systematic-review-and-meta-analysis
#20
Shao-Xue Ding, Tong Chen, Ting Wang, Chun-Yan Liu, Wen-Li Lu, Rong Fu
OBJECTIVES: This meta-analysis aimed to evaluate the risk of clonal evolution of granulocyte colony-stimulating factor (G-CSF) in acquired aplastic anemia (AA), and whether the use of G-CSF increases the occurrence of secondary malignant neoplasms, mainly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) or paroxysmal nocturnal hemoglobinuria (PNH). METHODS: Data were gathered from randomized controlled trials (RCTs) to evaluate the effect of G-CSF versus no G-CSF at the risk of developing the clonal complications of acquired AA...
2018: Acta Haematologica
keyword
keyword
159743
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"